TY  - JOUR
AU  - Schadendorf, Dirk
TI  - COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma.
JO  - Future oncology
VL  - 21
IS  - 21
SN  - 1479-6694
CY  - London
PB  - Taylor & Francis
M1  - DKFZ-2025-01535
SP  - 2701-2703
PY  - 2025
N1  - 2025 Sep;21(21):2701-2703 / MULTIMEDIA ARTICLE
AB  - This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.
KW  - 7-year update (Other)
KW  - BRAF V600 (Other)
KW  - COLUMBUS (Other)
KW  - Lead author commentary (Other)
KW  - binimetinib (Other)
KW  - encorafenib (Other)
KW  - melanoma (Other)
KW  - vemurafenib (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40705373
DO  - DOI:10.1080/14796694.2025.2536459
UR  - https://inrepo02.dkfz.de/record/303116
ER  -